Epilepsy

As per the Epilepsy foundation, approximately 3.4 million people live with epilepsy in the United States,
and over 150,000 new cases are diagnosed each year.

Among the European countries, the United Kingdom had the highest diagnosed Epileptic prevalent
population with 443,603 cases, followed by Germany, with Spain accounting for the lowest Epileptic
prevalence.

Epilepsy Therapeutic Market

The current Epilepsy treatment includes a combination of medications, diet therapy, and surgery. The
type of drugs or therapies prescribed to Epileptic patient depends on the severity of the case.

The commonly used epilepsy treatment therapy is Anti-Epileptic Medications (AEDs). The early treatment
choice for almost all patients with multiple seizures is AEDs. The medications effectively prevent and
control the seizures.

Anticonvulsant therapy is also considered after two unprovoked epileptic seizures. The medication
prescribed by the medical practitioner could be monotherapy or a combinational therapy including two
or more products as a medication.

According to DelveInsight’s studies, the Anti-Epileptic Medications (AEDs) are classified as Sodium Channel
Modulators, GammaAminobutyric Acid (GABA) Receptor Modulator, Calcium Channel Blockers, Receptor
Blockers, and others.
The current epilepsy therapies belong to these classes amongst which sodium channel modulators
occupies the maximum share followed by calcium channel blockers, and GABA Receptor Modulators. The
least used class involves calcium and sodium channel blocker and Cannabidiol.

Epilepsy Market

The total Epilepsy market size, as calculated by DelveInsight, was approximately USD 2,984 Million in 2017.
According to DelveInsight’s Epilepsy market analysis, the Epilepsy market size is expected to grow in the
coming years. Moreover, the total Epilepsy market size is set to show an extensive growth at a CAGR rate
of 8.85% for a study period of 2017-2028.

Expected launch of potential therapies may increase Epilepsy drug market size in the coming years.
Attributed to an increase in the diagnosed Epilepsy prevalent population, better diagnostics tools and
positive outcomes of the several drug candidates during the clinical trials, Epilepsy market is going to
move forward.

Key companies advancing Epilepsy Market

Key Pharma players such as Marinus Pharmaceuticals, Sage Therapeutics, SK Biopharmaceuticals, UCB,
Neurelis, Zogenix, Aquestive Therapeutics, INSYS Therapeutics, Engage Therapeutics, Zynerba Pharma,
etc. are the potent Healthcare companies creating a significant positive shift in the Epilepsy Market Size.
Upcoming drugs advancing Epilepsy Market

Cenobamate (YKP3089), Fintepla (ZX008), Ganaxolone, Natalizumab, and NRP2945are some of the
upcoming Epilpsy drugs that are going to grab the Epilepsy market share and advance quality of living of
the Epileptic patient pool.